Common Drug Review *

Submission Status

Product: Strattera

Generic Name: atomoxetine hydrochloride

Manufacturer: Eli Lilly Canada Inc.

Submission Type: Request for Advice

Date Submission Received: 2006-Sep-25

Date NOC Issued: 2004-Dec-24

Targeted CEDAC Meeting: 2007-Mar-21

Priority Review Granted: Not requested

	Phase	Target Time (Business Days)	Target Date**	Actual CDR Date	Comments
1	Submission Deemed Complete	5	2006-Oct-02	2006-Oct-02	ACP request for advice
2	CDR Reviewers' Reports Completed • Reviewers selected and contracted • Literature search and selection completed • Systematic review of clinical data completed • Critical appraisal of pharmacoeconomic (PE) data completed • Clinical and PE reports written • Reports edited and finalized • Reviewers' reports sent to manufacturer	45	2007-Jan-30	2007-Jan-31	Additional information requested November 10, 2006. Additional information requested December 1, 2006. Additional information received December 15, 2006.
3	Comments from Manufacturer on Reviewers' Reports Received by CDR	7	2007-Feb-08	2007-Feb-09	Due date for manufacturer comments February 9, 2007.
4	Reviewers' Reply to Manufacturer's Comments Completed	7	2007-Feb-19	2007-Feb-20	Due date for reviewers' replies February 20, 2007.
5	CEDAC Brief Completed and Sent to CEDAC Members	5	2007-Mar-07	2007-Mar-07	
6	CEDAC Meeting		2007-Mar-21	2007-Mar-21	
7	CEDAC Recommendation and Reasons for Recommendation Sent to Drug Plans, ACP and Manufacturer	5	2007-Mar-28	2007-Apr-03	Response to request for advice sent to drug plans, ACP and manufacturer on April 3, 2007. No CEDAC recommendation issued in response to this request for advice.
8	Embargo Period*** Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation	10			
9 (a)	Final Recommendation sent to Drug Plans, ACP, and Manufacturer (No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved)	5			
	OR				
9 (b)	Clarification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer (Clarification Requested, no Request for Reconsideration made)	5			
	OR				
9 (c)	Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request)	25 Depends on Meeting Dates			
10	Final Recommendation sent to Drug Plans, ACP, and Manufacturer	5			

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.